Barclays PLC Buys 71,463 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Barclays PLC grew its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 122.4% during the third quarter, Holdings Channel.com reports. The fund owned 129,839 shares of the company’s stock after purchasing an additional 71,463 shares during the quarter. Barclays PLC’s holdings in Caribou Biosciences were worth $255,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. PFM Health Sciences LP boosted its holdings in Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after purchasing an additional 223,299 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after buying an additional 536,162 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after buying an additional 124,782 shares during the last quarter. FMR LLC grew its holdings in shares of Caribou Biosciences by 7.4% in the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Caribou Biosciences during the second quarter valued at approximately $2,432,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Down 0.6 %

CRBU opened at $1.53 on Tuesday. The company has a market capitalization of $138.54 million, a price-to-earnings ratio of -0.93 and a beta of 2.34. The firm has a 50-day moving average price of $1.88 and a 200-day moving average price of $2.00. Caribou Biosciences, Inc. has a twelve month low of $1.50 and a twelve month high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. On average, sell-side analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on CRBU. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup cut their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Finally, Bank of America decreased their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.